Healios
4593.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥704m | ¥571m | ¥121m | ¥80m | — | — |
| Operating income | −¥2.3bn | −¥2.4bn | −¥3.2bn | −¥5.1bn | −¥5.3bn | — |
| Ordinary income | −¥2.4bn | −¥2.6bn | −¥3.0bn | −¥5.3bn | −¥5.5bn | −¥4.2bn |
| Total assets | ¥6.9bn | ¥4.1bn | ¥6.6bn | ¥9.2bn | ¥18.8bn | ¥18.4bn |
| Net assets / equity | ¥3.5bn | ¥824m | ¥1.1bn | ¥833m | ¥5.8bn | ¥5.6bn |
| EPS (basic) | ¥-22.58 | ¥-30.21 | ¥-42.37 | ¥-147.59 | ¥-104.06 | ¥-86.24 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 3
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 82 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 82 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 100 figures · EDINET |
22 more reports are still being processed.